IP Library › Granted Patent US 12,685,846
Granted Patent B2
US 12,685,846 · App. 18/644,542 · Granted Jul 21, 2026

Chemical ablation and method of treatment for various diseases

Inventors: Lixiao Wang (Henderson, NV); John J. Chen (Plymouth, MN); Yongxing Zhang (Irvine, CA)
Assignee: Neurotronic, Inc.
A61M25/1002A61B18/06A61K31/045A61M5/007A61M5/142A61M5/172A61M25/1011A61M29/02A61B2018/00577A61M2025/105A61M2025/1052A61M2202/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,685,846
App. No.
18/644,542
Filed
Apr 24, 2024
Granted
Jul 21, 2026
Kind
B2
Art Unit
3783
USPC
604/24
Abstract

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

Claims (52)

1 . A method for treating diabetes, the method comprising:

inserting a first delivery catheter into a body lumen at a first treatment site in the small intestine, duodenum, or jejunum;

delivering energy from the first delivery catheter to a tissue of the body lumen at the first treatment site, wherein the energy delivered from the first delivery catheter is effective to injure and/or damage the tissue at the first treatment site;

withdrawing the first delivery catheter from the first treatment site;

inserting a second delivery catheter that is the same or different as the first delivery catheter into a body lumen at a second treatment site in the small intestine, duodenum, or jejunum, wherein the second treatment site is a different treatment site than the first treatment site; and

delivering energy from the second delivery catheter to a tissue of the body lumen at the second treatment site, wherein the energy delivered from the second delivery catheter is effective to injure and/or damage the tissue at the second treatment site; and

withdrawing the second delivery catheter from the second treatment site;

wherein the injury and/or damage to the tissue at the first treatment site and to the tissue at the second treatment site is effective to have a benefit of relieving symptoms comprising reduction of HbA1c (A1c) and glucose level.

2 . The method of claim 1 , wherein the method is a method for treating diabetes and obesity, wherein the injury and/or damage to the tissue at the first treatment site and to the tissue at the second treatment site is effective to have a benefit of relieving symptoms comprising reduction of HbA1c (A1c), glucose level, and body weight.

3 . The method of claim 1 , wherein the first and second treatment sites are in the duodenum.

4 . The method of claim 1 , wherein the first treatment site is in the duodenum and the second treatment site is in the jejunum, or wherein the first treatment site is in the jejunum and the second treatment site is in the duodenum.

5 . The method of claim 1 , wherein the first and second treatment sites are in the jejunum.

6 . The method of claim 1 , wherein the energy delivered by the first and/or second delivery catheter comprises radiofrequency, cryoablation, microwave, laser, ultrasound, high intensity focused ultrasound, or a combination thereof.

7 . The method of claim 1 , wherein the energy delivered by the first and/or second delivery catheter comprises radiofrequency energy.

8 . The method of claim 1 , wherein the method further comprises infusing a chemical formulation from the first delivery catheter to the tissue of the body lumen at the first treatment site and/or infusing the chemical formulation from the second delivery catheter to the tissue of the body lumen at the second treatment site.

9 . The method of claim 8 , wherein the first and/or second delivery catheter comprises a needle catheter or a needle-based catheter.

10 . The method of claim 8 , wherein the first and/or second delivery catheter comprises a infusion catheter.

11 . The method of claim 8 , wherein the first and/or second delivery catheter comprises a balloon infusion catheter.

12 . The method of claim 8 , wherein the first and/or second delivery catheter comprises a balloon around a circumference of a shaft and the formulation infusion lumen in the shaft that passes through a region of the shaft that comprises the balloon thereon.

13 . The method of claim 12 , wherein the method further comprises:

inflating the balloon after the insertion to the first treatment site and deflating the balloon prior to the withdrawing from the first treatment site; and/or

inflating the balloon after the insertion to the second treatment site and deflating the balloon prior to the withdrawing from the second treatment site.

14 . The method of claim 8 , wherein the chemical formulation comprises ethanol, acetic acid, ethanol and water, an ethanol/water azeotrope, or ethanol and acetic acid.

15 . The method of claim 8 , wherein the chemical formulation comprises ethanol.

16 . The method of claim 8 , wherein the chemical formulation comprises ethanol and water.

17 . The method of claim 1 , further comprising:

inserting a third delivery catheter into a body lumen at a third treatment site in the small intestine, duodenum, or jejunum, wherein the third treatment site is a different treatment site than the first and second treatment sites;

delivering energy from the third delivery catheter to a tissue of the body lumen at the third treatment site, wherein the energy delivered from the third delivery catheter is effective to injure and/or damage the tissue at the third treatment site; and

withdrawing the third delivery catheter from the third treatment site.

18 . A method for treating diabetes, the method comprising:

inserting a first delivery catheter into a body lumen at a first treatment site in the small intestine, duodenum, or jejunum;

delivering energy from the first delivery catheter to a tissue of the body lumen at the first treatment site, wherein the energy delivered from the first delivery catheter is effective to injure and/or damage the tissue at the first treatment site;

withdrawing the first delivery catheter from the first treatment site;

inserting a second delivery catheter that is the same or different as the first delivery catheter into a body lumen at a second treatment site in the small intestine, duodenum, or jejunum, wherein the second treatment site is a different treatment site than the first treatment site;

delivering energy from the second delivery catheter to a tissue of the body lumen at the second treatment site, wherein the energy delivered from the second delivery catheter is effective to injure and/or damage the tissue at the second treatment site;

withdrawing the second delivery catheter from the second treatment site;

inserting a third delivery catheter into a body lumen at a third treatment site in the small intestine, duodenum, or jejunum, wherein the third treatment site is a different treatment site than the first and second treatment sites;

delivering energy from the third delivery catheter to a tissue of the body lumen at the third treatment site, wherein the energy delivered from the third delivery catheter is effective to injure and/or damage the tissue at the third treatment site; and

withdrawing the third delivery catheter from the third treatment site;

wherein the injury and/or damage to the tissue at the first treatment site, at the second treatment site, and at the third treatment site is effective to have a benefit of relieving symptoms comprising reduction of HbA1c (A1c) and glucose level.

19 . The method of claim 18 , wherein the method is a method of treating diabetes and obesity, wherein the injury and/or damage to the tissue at the first treatment site, second treatment site, and third treatment site is effective to have a benefit of relieving symptoms comprising reduction of HbA1c (A1c), glucose level, and body weight.

20 . The method of claim 18 , wherein the first treatment site, the second treatment site, and the third treatment site are non-overlapping treatment sites spaced apart along the duodenum or jejunum.

21 . A method for treating diabetes and obesity, the method comprising:

inserting a first delivery catheter into a body lumen at a first treatment site in the small intestine, duodenum, or jejunum;

delivering energy from the first delivery catheter to a tissue of the body lumen at the first treatment site, wherein the energy delivered by the first delivery catheter is effective to injure and/or damage the tissue at the first treatment site;

withdrawing the first delivery catheter from the first treatment site;

inserting a second delivery catheter into a body lumen at a second treatment site in the small intestine, duodenum, or jejunum, wherein the second treatment site is a different treatment site than the first treatment site; and

delivering energy from the second delivery catheter to a tissue of the body lumen at the second treatment site, wherein the energy delivered by the second delivery catheter is effective to injure and/or damage the tissue at the second treatment site; and

withdrawing the second delivery catheter from the second treatment site;

wherein the injury and/or damage to the tissue at the first treatment site and to the tissue at the second treatment site is effective to have a benefit of relieving symptoms comprising reduction of HbA1c (A1c), glucose level, and body weight.

22 . The method of claim 1 , wherein the first treatment site and the second treatment site are non-overlapping treatment sites spaced apart along the duodenum or jejunum.

23 . The method of claim 21 , wherein the first treatment site and the second treatment site are non-overlapping treatment sites spaced apart along the duodenum or jejunum.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2024
From: WANG, LIXIAO; CHEN, JOHN J.; ZHANG, YONGXING
To: NEUROTRONIC, INC.
Reel/Frame 067211/0722 →
Continuity (15)
Continuation 17010271 · Sep 2, 2020
Continuation In Part 16986717 · Aug 6, 2020
Continuation In Part 16563192 · Sep 6, 2019
Continuation 16563213 · Sep 6, 2019
Continuation 16419587 · May 22, 2019
Continuation 16156163 · Oct 10, 2018
Continuation 15521973 · Oct 30, 2015
Continuation 14438411 · Oct 30, 2013
Provisional Application 62124868 · Jan 5, 2015
Provisional Application 62122818 · Oct 30, 2014
Provisional Application 61849928 · Feb 5, 2013
Provisional Application 61848483 · Jan 4, 2013
Provisional Application 61797647 · Dec 12, 2012
Provisional Application 61796118 · Nov 2, 2012
Related Publication 20240277977A1 · Aug 22, 2024
References Cited (400)
US 4254056A · Konno et al. · 1981 [cited by applicant]
US 4573966A · Welkl et al. · 1986 [cited by applicant]
US 4653438A · Russell · 1987 [cited by applicant]
US 4684363A · Ari et al. · 1987 [cited by applicant]
US 5045061A · Seifert et al. · 1991 [cited by applicant]
US 5263931A · Miller · 1993 [cited by applicant]
US 5314443A · Rudnick · 1994 [cited by applicant]
US 5315992A · Dalton · 1994 [cited by applicant]
US 5380284A · Don · 1995 [cited by applicant]
US 5419763A · Hildebrand · 1995 [cited by applicant]
US 5423755A · Kesten et al. · 1995 [cited by applicant]
US 5460610A · Don · 1995 [cited by applicant]
US 5599307A · Bacher et al. · 1997 [cited by applicant]
US 5681281A · Vigil et al. · 1997 [cited by applicant]
US 5720735A · Dorros · 1998 [cited by applicant]
US 6048332A · Duffy et al. · 2000 [cited by applicant]
US 6062223A · Palazzo et al. · 2000 [cited by applicant]
US 6135981A · Dyke · 2000 [cited by applicant]
US 6148222A · Ramsey, III · 2000 [cited by applicant]
US 6217554B1 · Green · 2001 [cited by applicant]
US 6258087B1 · Edwards et al. · 2001 [cited by applicant]
US 6444233B1 · Arntzen et al. · 2002 [cited by applicant]
US 6623452B2 · Chien et al. · 2003 [cited by applicant]
US 6685672B1 · Forman · 2004 [cited by applicant]
US 7617005B2 · Demarais et al. · 2009 [cited by applicant]
US 7653438B2 · Deem et al. · 2010 [cited by applicant]
US 7717948B2 · Demarais et al. · 2010 [cited by applicant]
US 8052668B2 · Sih · 2011 [cited by applicant]
US 8128592B2 · Mitelberg · 2012 [cited by examiner]
US 8372054B2 · Duffy et al. · 2013 [cited by applicant]
US 8740849B1 · Fischell et al. · 2014 [cited by applicant]
US 8840601B2 · Salahieh et al. · 2014 [cited by applicant]
US 9114123B2 · Vafai et al. · 2015 [cited by applicant]
US 10286191B2 · Wang et al. · 2019 [cited by applicant]
US 10537375B2 · Wang · 2020 [cited by applicant]
US 10758713B2 · Wang et al. · 2020 [cited by applicant]
US 11382689B2 · Wang · 2022 [cited by applicant]
US 11517725B2 · Wang et al. · 2022 [cited by applicant]
US 11648378B2 · Wang et al. · 2023 [cited by applicant]
US 11684417B2 · Wang · 2023 [cited by applicant]
US 12005207B2 · Wang et al. · 2024 [cited by applicant]
US 12193731B2 · Wang · 2025 [cited by applicant]
US 12208224B2 · Wang et al. · 2025 [cited by applicant]
US 20020014238A1 · Kotmel · 2002 [cited by applicant]
US 20020068953A1 · Kokish · 2002 [cited by applicant]
US 20020177846A1 · Mulier · 2002 [cited by applicant]
US 20030066532A1 · Gobel · 2003 [cited by applicant]
US 20040064150A1 · Becker · 2004 [cited by applicant]
US 20040089313A1 · Utley · 2004 [cited by examiner]
US 20040116852A1 · Scopton · 2004 [cited by applicant]
US 20040267336A1 · Morrison et al. · 2004 [cited by applicant]
US 20050288639A1 · Hibner · 2005 [cited by applicant]
US 20060161233A1 · Barry et al. · 2006 [cited by applicant]
US 20060235474A1 · Demarais · 2006 [cited by applicant]
US 20060265014A1 · Demarais et al. · 2006 [cited by applicant]
US 20060282120A1 · Sih · 2006 [cited by applicant]
US 20070077230A1 · Mon · 2007 [cited by applicant]
US 20080051721A1 · Carter et al. · 2008 [cited by applicant]
US 20080114297A1 · Barry et al. · 2008 [cited by applicant]
US 20080118544A1 · Wang · 2008 [cited by applicant]
US 20080208118A1 · Goldman · 2008 [cited by applicant]
US 20080255508A1 · Wang · 2008 [cited by applicant]
US 20080255509A1 · Wang · 2008 [cited by applicant]
US 20080275445A1 · Kelly · 2008 [cited by examiner]
US 20090192505A1 · Askew et al. · 2009 [cited by applicant]
US 20090301483A1 · Barry et al. · 2009 [cited by applicant]
US 20100010470A1 · Bates · 2010 [cited by applicant]
US 20100087781A1 · Adams et al. · 2010 [cited by applicant]
US 20100145304A1 · Cressman · 2010 [cited by applicant]
US 20100209472A1 · Wang · 2010 [cited by applicant]
US 20110093000A1 · Ogle et al. · 2011 [cited by applicant]
US 20110104061A1 · Seward · 2011 [cited by applicant]
US 20110152683A1 · Gerrans et al. · 2011 [cited by applicant]
US 20110182912A1 · Evans et al. · 2011 [cited by applicant]
US 20110218564A1 · Drasler et al. · 2011 [cited by applicant]
US 20120083809A1 · Drasler et al. · 2012 [cited by applicant]
US 20120116438A1 · Salahieh et al. · 2012 [cited by applicant]
US 20120197245A1 · Burnett et al. · 2012 [cited by applicant]
US 20120209251A1 · Bates · 2012 [cited by applicant]
US 20120215212A1 · Selzer et al. · 2012 [cited by applicant]
US 20120259269A1 · Meyer · 2012 [cited by applicant]
US 20120271277A1 · Fischell et al. · 2012 [cited by applicant]
US 20120271301A1 · Fischell et al. · 2012 [cited by applicant]
US 20130053792A1 · Fischell et al. · 2013 [cited by applicant]
US 20130138082A1 · Salahieh et al. · 2013 [cited by applicant]
US 20130178910A1 · Azamian et al. · 2013 [cited by applicant]
US 20130189190A1 · Wang · 2013 [cited by applicant]
US 20130204068A1 · Gnanashanmugam et al. · 2013 [cited by applicant]
US 20130245665A1 · Scandurra et al. · 2013 [cited by applicant]
US 20140243872A1 · Cordray · 2014 [cited by applicant]
US 20140371736A1 · Levin et al. · 2014 [cited by applicant]
US 20150005805A1 · Kesten et al. · 2015 [cited by applicant]
US 20150056298A1 · Azamian et al. · 2015 [cited by applicant]
US 20150224289A1 · Seward · 2015 [cited by applicant]
US 20150272666A1 · Wang · 2015 [cited by applicant]
US 20150305943A1 · Hossainy et al. · 2015 [cited by applicant]
US 20160135879A1 · Beasley et al. · 2016 [cited by applicant]
US 20160310200A1 · Wang · 2016 [cited by applicant]
US 20170007310A1 · Rajagopalan et al. · 2017 [cited by applicant]
US 20180015264A1 · Wang et al. · 2018 [cited by applicant]
US 20180185618A1 · Sweeney · 2018 [cited by applicant]
US 20190015639A1 · Wang et al. · 2019 [cited by applicant]
US 20190038881A1 · Wang et al. · 2019 [cited by applicant]
US 20190076186A1 · Fischell et al. · 2019 [cited by applicant]
US 20190167918A1 · Fischell et al. · 2019 [cited by applicant]
US 20190307507A1 · Wang · 2019 [cited by applicant]
US 20190388147A1 · Wang · 2019 [cited by applicant]
US 20200009355A1 · Wang et al. · 2020 [cited by applicant]
US 20200016379A1 · Wang et al. · 2020 [cited by applicant]
US 20200086093A1 · Wang · 2020 [cited by applicant]
US 20200230373A1 · Stankus et al. · 2020 [cited by applicant]
US 20200360671A1 · Wang et al. · 2020 [cited by applicant]
US 20200398032A1 · Wang et al. · 2020 [cited by applicant]
US 20210275784A1 · Wang · 2021 [cited by applicant]
US 20210275785A1 · Wang · 2021 [cited by applicant]
US 20210275786A1 · Wang · 2021 [cited by applicant]
US 20210275787A1 · Wang · 2021 [cited by applicant]
US 20220233238A1 · Wang et al. · 2022 [cited by applicant]
US 20220233827A1 · Wang et al. · 2022 [cited by applicant]
US 20230075851A1 · Mayse et al. · 2023 [cited by applicant]
US 20230270489A1 · Wang · 2023 [cited by applicant]
US 20240277976A1 · Wang et al. · 2024 [cited by applicant]
US 20250025673A1 · Wang · 2025 [cited by applicant]
US 20250082400A1 · Wang · 2025 [cited by applicant]
US 20250352774A1 · Wang et al. · 2025 [cited by applicant]
CN 1593359A · 2005 [cited by applicant]
CN 101035593A · 2007 [cited by applicant]
CN 101861184A · 2010 [cited by applicant]
CN 102481428A · 2012 [cited by applicant]
CN 102573466A · 2012 [cited by applicant]
CN 102600546A · 2012 [cited by applicant]
CN 102698354A · 2012 [cited by applicant]
CN 102727986A · 2012 [cited by applicant]
CN 102743163A · 2012 [cited by applicant]
CN 107106820A · 2017 [cited by applicant]
CN 110772311A · 2020 [cited by applicant]
CN 113040895A · 2021 [cited by applicant]
CN 114025826A · 2022 [cited by applicant]
CN 118555975 · 2024 [cited by applicant]
EP 2497524A1 · 2012 [cited by applicant]
EP 2914326B1 · 2023 [cited by applicant]
EP 4230162 · 2024 [cited by applicant]
JP S5769814A · 1982 [cited by applicant]
JP H04215767A · 1992 [cited by applicant]
JP H07308382A · 1995 [cited by applicant]
JP 08508917A · 1996 [cited by applicant]
JP 2000279524A · 2000 [cited by applicant]
JP 2004035128A · 2004 [cited by applicant]
JP 2004180892A · 2004 [cited by applicant]
JP 2004528924A · 2004 [cited by applicant]
JP 2005506101A · 2005 [cited by applicant]
JP 2006502801A · 2006 [cited by applicant]
JP 2010078379A · 2010 [cited by applicant]
JP 2010519005A · 2010 [cited by applicant]
JP 2010528815A · 2010 [cited by applicant]
JP 2011519699A · 2011 [cited by applicant]
JP 2012505050A · 2012 [cited by applicant]
JP 2012508067A · 2012 [cited by applicant]
JP 2012517858A · 2012 [cited by applicant]
JP 2012524808A · 2012 [cited by applicant]
JP 2013517847A · 2013 [cited by applicant]
JP 2014524342A · 2014 [cited by applicant]
JP 2014527272A · 2014 [cited by applicant]
JP 2015536945A · 2015 [cited by applicant]
JP 2017533036A · 2017 [cited by applicant]
JP 6389185B2 · 2018 [cited by applicant]
JP 2018153239A · 2018 [cited by applicant]
JP 2020178075 · 2020 [cited by applicant]
JP 2020189858A · 2020 [cited by applicant]
JP 2021046397A · 2021 [cited by applicant]
JP 2022017822 · 2022 [cited by applicant]
JP 2022538239A · 2022 [cited by applicant]
JP 2023027052A · 2023 [cited by applicant]
JP 2024544038 · 2024 [cited by applicant]
JP 2024170628 · 2024 [cited by applicant]
JP 7622980 · 2025 [cited by applicant]
JP 2025111789 · 2025 [cited by applicant]
WO WO9421320A1 · 1994 [cited by applicant]
WO WO9618427A1 · 1996 [cited by applicant]
WO WO9717099A1 · 1997 [cited by applicant]
WO WO02051490A1 · 2002 [cited by applicant]
WO WO2006055695A1 · 2006 [cited by applicant]
WO WO2008106357A1 · 2008 [cited by applicant]
WO WO2009076732A1 · 2009 [cited by applicant]
WO WO2009082433A2 · 2009 [cited by applicant]
WO WO2010033686A1 · 2010 [cited by applicant]
WO WO2010124120A1 · 2010 [cited by applicant]
WO WO0119445A1 · 2011 [cited by applicant]
WO WO2011094367A1 · 2011 [cited by applicant]
WO WO2011119159A1 · 2011 [cited by applicant]
WO WO2013026565A1 · 2013 [cited by applicant]
WO WO2013028781A1 · 2013 [cited by applicant]
WO WO2013067382A1 · 2013 [cited by applicant]
WO WO2013090848A1 · 2013 [cited by applicant]
WO WO2014070820A2 · 2014 [cited by applicant]
WO WO2015058296A1 · 2015 [cited by applicant]
WO WO2016070032A1 · 2016 [cited by applicant]
WO WO2020264152A1 · 2020 [cited by applicant]
WO WO2023091475A1 · 2023 [cited by applicant]
Sikaris, Title: “The Correlation of Hemoglobin A1c to Blood Glucose”, Journal of Diabetes Science and Technology, vol. 3, Issue 3, May 2009. (Year: 2009). [cited by examiner]
Matthes et al., “Concentration-dependent ablation of pancreatic tissue by EUS-guided ethanol injection”, Gastrointestinal Endoscopy, vol. 65, No. 2, year:2007. (Year: 2007). [cited by examiner]
de Jonge et al., Endoscopic Duodenal-Jejunal Bypass Liner Rapidly Improves Type 2 Diabetes, Springer Science+Business Media New York, Mar. 23, 2013. (Year: 2013). [cited by examiner]
“U.S. Appl. No. 14/438,411, Advisory Action mailed Apr. 30, 2019”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Final Office Action mailed Feb. 25, 2019”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Final Office Action mailed May 9, 2018”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Non Final Office Action mailed Sep. 21, 2018”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Non Final Office Action mailed Oct. 20, 2017”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Preliminary Amendment filed Jul. 28, 2015”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Jan. 17, 2018 to Non Final Office Action mailed Oct. 20, 2017”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Apr. 16, 2019 to Final Office Action mailed Feb. 25, 2019”, 18 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Aug. 7, 2018 to Final Office Action mailed May 9, 2018”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Aug. 25, 2017 to Restriction Requirement mailed Jul. 14, 2017”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Oct. 8, 2018 to Non Final Office Action mailed Sep. 21, 2018”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 14/438,411, Restriction Requirement mailed Jul. 14, 2017”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Advisory Action mailed Jul. 30, 2019”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Corrected Notice of Allowability mailed Nov. 20, 2019”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Final Office Action mailed May 3, 2019”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Final Office Action mailed Aug. 16, 2018”, 26 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Non Final Office Action mailed Feb. 15, 2018”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Non Final Office Action mailed Nov. 30, 2018”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Notice of Allowance mailed Oct. 1, 2019”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Preliminary Amendment filed Apr. 20, 2016”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Mar. 20, 2019 to Non Final Office Action mailed Nov. 30, 2018”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Jun. 14, 2018 to Non Final Office Action mailed Feb. 15, 2018”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Jul. 1, 2019 to Final Office Action mailed May 3, 2019”, 20 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Oct. 26, 2018 to Final Office Action mailed Aug. 16, 2018”, 20 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Dec. 27, 2017 to Restriction Requirement mailed Oct. 31, 2017”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/133,976, Restriction Requirement mailed Oct. 31, 2017”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Examiner Interview Summary mailed Jun. 4, 2018”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Final Office Action mailed Jan. 15, 2019”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Non Final Office Action mailed May 18, 2018”, 21 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Non Final Office Action mailed Sep. 14, 2018”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Notice of Allowance mailed Mar. 27, 2019”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Preliminary Amendment filed Apr. 26, 2017”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Response filed Mar. 14, 2019 to Final Office Action mailed Jan. 15, 2019”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 15/521,973, Response filed Dec. 10, 2018 to Non Final Office Action mailed Sep. 14, 2018”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,163, Non Final Office Action mailed Apr. 2, 2020”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,163, Notice of Allowance mailed Jul. 22, 2020”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,163, Response filed Jul. 1, 2020 to Non Final Office Action mailed Apr. 2, 2020”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/419,587, Corrected Notice of Allowability mailed Apr. 27, 2022”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/419,587, Final Office Action mailed Feb. 24, 2022”, 18 pgs. [cited by applicant]
“U.S. Appl. No. 16/419,587, Non Final Office Action mailed Oct. 5, 2021”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 16/419,587, Notice of Allowance mailed Apr. 11, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/419,587, Preliminary Amendment filed Jul. 9, 2019”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 16/419,587, Response filed Mar. 9, 2022 to Final Office Action mailed Feb. 24, 2022”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/419,587, Response filed Nov. 4, 2021 to Non Final Office Action mailed Oct. 5, 2021”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,192, Non Final Office Action mailed Nov. 30, 2022”, 21 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,192, Notice of Allowance mailed Mar. 8, 2023”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,192, Response filed Feb. 9, 2023 to Non Final Office Action mailed Nov. 30, 2022”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,213, Non Final Office Action mailed Sep. 15, 2022”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,213, Notice of Allowability mailed Mar. 1, 2023”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,213, Notice of Allowance mailed Feb. 3, 2023”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,213, Response filed Dec. 13, 2022 to Non Final Office Action mailed Sep. 15, 2022”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,235, Non Final Office Action mailed May 12, 2022”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,235, Non Final Office Action mailed Sep. 30, 2021”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,235, Notice of Allowance mailed Feb. 11, 2022”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,235, Notice of Allowance mailed Aug. 26, 2022”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,235, Response filed Aug. 11, 2022 to Non Final Office Action mailed May 12, 2022”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/563,235, Response filed Nov. 16, 2021 to Non Final Office Action mailed Sep. 30, 2021”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Advisory Action mailed Jul. 26, 2023”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Final Office Action mailed May 15, 2023”, 26 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Final Office Action mailed Jul. 26, 2022”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Non Final Office Action mailed Feb. 6, 2023”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Non Final Office Action mailed Apr. 5, 2022”, 23 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Non Final Office Action mailed Aug. 24, 2023”, 23 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Apr. 18, 2023 to Non Final Office Action mailed Feb. 6, 2023”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Jul. 5, 2022 to Non Final Office Action mailed Apr. 5, 2022”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Jul. 13, 2023 to Final Office Action mailed May 15, 2023”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Oct. 26, 2022 to Final Office Action mailed Jul. 26, 2022”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,717, Final Office Action mailed Nov. 1, 2023”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,717, Non Final Office Action mailed May 31, 2023”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,717, Notice of Allowance mailed Feb. 14, 2024”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,717, Response filed Jan. 25, 2024 to Final Office Action mailed Nov. 1, 2023”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,717, Response filed Apr. 19, 2023 to Restriction Requirement mailed Mar. 2, 2023”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,717, Response filed Aug. 9, 2023 to Non Final Office Action mailed May 31, 2023”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/986,717, Restriction Requirement mailed Mar. 2, 2023”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/329,765, Restriction Requirement mailed Sep. 13, 2023”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 17/329,795, Restriction Requirement mailed Sep. 13, 2023”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 17/329,823, Restriction Requirement mailed Sep. 13, 2023”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 17/329,842, Restriction Requirement mailed Oct. 17, 2023”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 18/144,368, Non Final Office Action mailed Apr. 12, 2024”, 16 pgs. [cited by applicant]
“Chinese Application Serial No. 202080046425.X, Voluntary Amendment filed Jun. 14, 2022”, w/English Claims, 12 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed Jan. 17, 2018”, (English Translation), 8 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed Feb. 19, 2019”, W/English Translation, 6 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed May 19, 2017”, w/English Translation, 18 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed Dec. 27, 2019”, w/English translation, 12 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed Apr. 2, 2018 to Office Action mailed Jan. 17, 2018”, w/English claims, 15 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed Aug. 23, 2019 to Office Action mailed Feb. 19, 2019”, w/English Claims, 14 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed Oct. 9, 2017 to Office Action mailed May 19, 2017”, w/English Claims, 16 pgs. [cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed 11-27-8 to Office Action mailed”, w/English Claims, 16 pgs. [cited by applicant]
“Chinese Application Serial No. 201580058938.1, Office Action mailed Jul. 2, 2020”, w/English translation, 14 pgs. [cited by applicant]
“Chinese Application Serial No. 201580058938.1, Office Action mailed Sep. 3, 2019”, W/English Translation, 17 pgs. [cited by applicant]
“Chinese Application Serial No. 201580058938.1, Response filed Mar. 18, 2020 to Office Action mailed Sep. 3, 2019”, w/English Claims, 15 pgs. [cited by applicant]
“Chinese Application Serial No. 201580058938.1, Response filed Nov. 24, 2020 to Office Action mailed Jul. 2, 2020”, w/English Claims, 16 pgs. [cited by applicant]
“Chinese Application Serial No. 201580058938.1, Voluntary Amendment mailed Feb. 22, 2018”. w/English Claims, 21 pgs. [cited by applicant]
“Chinese Application Serial No. 201910917938.2, Decision of Rejection mailed Mar. 14, 2023”, w/English translation, 13 pgs. [cited by applicant]
“Chinese Application Serial No. 201910917938.2, Office Action mailed May 20, 2022”, w/English translation, 16 pgs. [cited by applicant]
“Chinese Application Serial No. 201910917938.2, Office Action mailed Oct. 18, 2022”, w/English translation, 7 pgs. [cited by applicant]
“Chinese Application Serial No. 201910917938.2, Response filed Feb. 27, 2023 to Office Action mailed Oct. 18, 2022”, w/ English Claims, 8 pgs. [cited by applicant]
“Chinese Application Serial No. 201910917938.2, Response filed Jun. 28, 2023 to Decision of Rejection mailed Mar. 14, 2023”, w/ English Claims, 13 pgs. [cited by applicant]
“Chinese Application Serial No. 201910917938.2, Response filed Sep. 28, 2022 to Office Action mailed May 20, 2022”, w/ English Claims, 7 pgs. [cited by applicant]
“Chinese Application Serial No. 202110227749.X, Office Action mailed Dec. 22, 2023”, w/English Translation, 8 pgs. [cited by applicant]
“Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma”. A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial Am J Respir Crit Care Med vol. 181., (2010), 9 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Communication Pursuant to Article 94(3) EPC mailed Mar. 20, 2020”, 7 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Communication Pursuant to Article 94(3) EPC mailed Jun. 1, 2018”, 9 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Extended European Search Report mailed Jun. 6, 2016”, 6 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Invitation pursuant to Article 94(3) and Rule 71(1) EPC mailed Oct. 11, 2022”, 4 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Office Action mailed Jun. 12, 2015”, 3 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Response filed Jul. 20, 2020 to Communication Pursuant to Article 94(3) EPC mailed Mar. 20, 2020”, 13 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Response filed Aug. 10, 2022 to Summons to Attend Oral Proceedings mailed Feb. 28, 2022”, 52 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Response filed Oct. 19, 2015 to Office Action mailed Jun. 12, 2015”, 13 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Response filed Dec. 1, 2016 to Extended European Search Report mailed Jun. 6, 2016”, 20 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Summons to Attend Oral Proceedings mailed Jan. 28, 2022”, 10 pgs. [cited by applicant]
“European Application Serial No. 13851462.5, Summons to Attend Oral Proceedings mailed Feb. 28, 2022”, 4 pgs. [cited by applicant]
“European Application Serial No. 15853911.4, Communication Pursuant to Article 94(3) EPC mailed Apr. 28, 2022”, 10 pgs. [cited by applicant]
“European Application Serial No. 15853911.4, Communication Pursuant to Article 94(3) EPC mailed Apr. 30, 2020”, 8 pgs. [cited by applicant]
“European Application Serial No. 15853911.4, Extended European Search Report mailed May 30, 2018”, 15 pgs. [cited by applicant]
“European Application Serial No. 15853911.4, Reponse filed Nov. 12, 2018 to Extended European Search Report mailed May 30, 2018”, 17 pgs. [cited by applicant]
“European Application Serial No. 15853911.4, Response filed Sep. 2, 2022 to Communication Pursuant to Article 94(3) EPC mailed Apr. 28, 2022”, 116 pgs. [cited by applicant]
“European Application Serial No. 15853911.4, Response filed Oct. 27, 2020 to Communication Pursuant to Article 94(3) EPC mailed Apr. 30, 2020”, 14 pgs. [cited by applicant]
“European Application Serial No. 20832727.0, Extended European Search Report mailed Feb. 28, 2023”, 9 pgs. [cited by applicant]
“European Application Serial No. 20832727.0, Response filed Sep. 26, 2023 to Communication pursuant to Rules 70(2) and 70a(2) EPC mailed Mar. 17, 2023”, 15 pgs. [cited by applicant]
“European Application Serial No. 20832727.0, Response to Communication pursuant to Rules 161 and 162 filed Aug. 19, 2022”, 13 pgs. [cited by applicant]
“European Application Serial No. 23183741.0, Extended European Search Report mailed Jul. 21, 2023”, 14 pgs. [cited by applicant]
“European Application Serial No. 23183741.0, Response filed Feb. 19, 2024 to Extended European Search Report mailed Jul. 21, 2023”, 12 pgs. [cited by applicant]
“International Application Serial No. PCT/US2015/058296, International Preliminary Report on Patentability mailed May 11, 2017”, 9 pgs. [cited by applicant]
“International Application Serial No. PCT/US2015/058296, International Search Report mailed Jan. 21, 2016”, 2 pgs. [cited by applicant]
“International Application Serial No. PCT/US2015/058296, Written Opinion mailed Jan. 21, 2016”. 7 pgs. [cited by applicant]
“International Application Serial No. PCT/US2020/039605, International Preliminary Report Jon Patentability mailed Jan. 6, 2022”, 9 pgs. [cited by applicant]
“International Application Serial No. PCT/US2020/039605, International Search Report mailed Sep. 28, 2020”, 2 pgs. [cited by applicant]
“International Application Serial No. PCT/US2020/039605, Written Opinion mailed Sep. 28, 2020”, 7 pgs. [cited by applicant]
“International Application Serial No. PCT/US2022/050087, International Search Report mailed Mar. 1, 2023”, 3 pgs. [cited by applicant]
“International Application Serial No. PCT/US2022/050087, Written Opinion mailed Mar. 1, 2023”, 4 pgs. [cited by applicant]
“Japanese Application Serial No. 2015-540733, Office Action mailed Jul. 4, 2017”, w/English Translation, 12 pgs. [cited by applicant]
“Japanese Application Serial No. 2015-540733, Office Action mailed Dec. 29, 2017”, With English Translation, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2015-540733, Response filed Mar. 16, 2018 to Office Action mailed Dec. 29, 2017”, w/ English Claims, 11 pgs. [cited by applicant]
“Japanese Application Serial No. 2015-540733, Response filed Oct. 4, 2017 to Office Action mailed Jul. 4, 2017”, w/ English Claims, 19 pgs. [cited by applicant]
“Japanese Application Serial No. 2017-523517, Notification of Reasons for Refusal mailed Jul. 6, 2021”, w/ English Translation, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2017-523517, Notification of Reasons for Rejection mailed Sep. 10, 2019”, w/ English Translation, 13 pgs. [cited by applicant]
“Japanese Application Serial No. 2017-523517, Office Action mailed Jun. 23, 2020”, w/ English translation, 14 pgs. [cited by applicant]
“Japanese Application Serial No. 2017-523517, Response filed Mar. 6, 2020 to Notification of Reasons for Rejection mailed Sep. 10, 2019”, w/English Claims, 14 pgs. [cited by applicant]
“Japanese Application Serial No. 2017-523517, Response filed Oct. 23, 2020 to Office Action mailed Jun. 23, 2020”, w/English Claims, 14 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Examiners Decision of Final Refusal mailed Apr. 7, 2020”, w/ English Translation, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Notification of Reasons for Refusal mailed Jan. 5, 2022”, w/ English Translation, 17 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Notification of Reasons for Refusal mailed Jul. 2, 2019”, W/ English Translation, 16 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Notification of Reasons for Refusal mailed Aug. 17, 2021”, w/ English Translation, 17 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Office Action mailed Nov. 8, 2022”, w/ English Translation, 45 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Response filed Apr. 5, 2022 to Notification of Reasons for Refusal mailed Jan. 5, 2022”, w/ English Claims, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Response filed Oct. 1, 2019 to Notification of Reasons for Refusal mailed Jul. 2, 2019”, w/English Claims, 10 pgs. [cited by applicant]
“Japanese Application Serial No. 2018-153239, Response filed Nov. 16, 2021 to Notification of Reasons for Refusal mailed Aug. 17, 2021”, w/Engilsh Claims, 10 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-134047, Examiners Decision of Final Refusal mailed Jun. 21, 2022”, w/ English translation, 6 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-134047, Notification of Reasons for Refusal mailed Sep. 28, 2021”, w/ English Translation, 16 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-134047, Response filed Mar. 28, 2022 to Notification of Reasons for Refusal mailed Sep. 28, 2021”, w/ English translation, 21 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-178075, Notification of Reasons for Refusal mailed Jan. 5, 2022”, w/ English Translation, 8 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-178075, Office Action mailed Nov. 22, 2022”, w/o English Translation, 1 pg. [cited by applicant]
“Japanese Application Serial No. 2020-178075, Preliminary Examination Report mailed Jan. 24, 2023”, w/ English Translation, 2 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-178075, Response field Dec. 21, 2022 to Office Action mailed Nov. 22, 2022”, w/English Translation, 11 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-178075, Response filed Apr. 5, 2022 to Notification of Reasons for Refusal mailed Jan. 5, 2022”, w English translation, 6 pgs. [cited by applicant]
“Japanese Application Serial No. 202080044525.9, Examiners Decision of Final Refusal mailed Jul. 5, 2022”, w/ English Translation, 8 pgs. [cited by applicant]
“Japanese Application Serial No. 202080044525.9, Response filed Nov. 7, 2022 to Examiners Decision of Final Refusal mailed Jul. 5, 2022”, w/ English Claims, 13 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-169101, Notification of Reasons for Rejection mailed Oct. 31, 2023”, W/ English Translation, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-169101, Response filed Jan. 30, 2024 to Notification of Reasons for Rejection mailed Oct. 31, 2023”, w/ English Claims, 14 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-169101, Voluntary Amendment filed Jun. 19, 2023”, 15 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-178135, Notification of Reasons for Refusal mailed Nov. 11, 2023”, w/ English Translation, 10 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-178135, Response filed Feb. 27, 2024 to Notification of Reasons for Refusal mailed Nov. 11, 2023”, w/ english claims, 9 pgs. [cited by applicant]
Dunican, Eleanor M, “Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction”, J Clin Invest. 2018;128(3), (2018), 14 pgs. [cited by applicant]
Greer, M, et al., “Paclitaxel-Coated Balloons in Refractory Nonanastomostic Airway Stenosis Following Lung Transplantation”, American Journal of Transplantation 2014 14: 2400-2405, (2014), 2400-2405. [cited by applicant]
Kim, K. C., et al., “Airway goblet cell mucin: its structure and regulation of secretion”, Series Airway Mucus Eur Respir J 1997; 10:, (1997), pp. 2644-2649. [cited by applicant]
Krmisky, William, et al., “Thermal ablation for asthma: current status and technique”, J Thorac Dis 2017;9(Suppl 2):S104-S109, (2017), 6 pgs. [cited by applicant]
Krum, H., et al., “Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.”, Lancet, 373(9671), (2009), 2375-1281. [cited by applicant]
Menzella, Francesco, et al., “Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights”, Journal of Asthma and Allergy 2020:13, (2020), 13 pgs. [cited by applicant]
Peters, Michael C, et al., “Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency”, Am J Respir Crit Care Med vol. 202, Iss 7, (2020), 10 pgs. [cited by applicant]
Sakata, Kenneth K, et al., “Paclitaxel-coated balloon dilation for central airway obstruction”, Respiratory Medicine Case Reports 24, (2018), 129-132. [cited by applicant]
Tian, Juanhua, et al., “Rectifying disorder of extracellularmatrix to suppress urethral stricture by protein nanofilm-controlled drug delivery from urinary catheter”, nature communications, (May 17, 2023), 17 pgs. [cited by applicant]
“Chinese Application Serial No. 202110227749.X, Response filed May 6, 2024 to Office Action mailed Dec. 22, 2023”, w current English claims, 15 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-169101, Examiners Decision of Final Refusal mailed May 14, 2024”, W English Translation, 4 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-178075, Notification of Reasons for Rejection mailed May 14, 2024”, W English Translation, 25 pgs. [cited by applicant]
“Recording of clinical analysis research association”, w English translation No. 5, [Online] Retrieved from the internet: http: www.jrsca.jp contents records contents Pdf 5-PDF?, (Feb. 2005), 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/010,271, Restriction Requirement mailed May 22, 2024”, 7 pgs. [cited by applicant]
“International Application Serial No. PCT US2022 050087, International Preliminary Report on Patentability mailed May 30, 2024”, 6 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-178135, Notification of Reasons for Refusal mailed Jun. 4, 2024”, w English translation, 6 pgs. [cited by applicant]
“U.S. Appl. No. 17/010,271, Response filed Jun. 12, 2024 to Restriction Requirement mailed May 22, 2024”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 18/295,961, Non Final Office Action mailed Jun. 21, 2024”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 18/144,368, Response filed Jul. 2, 2024 to Non Final Office Action mailed Apr. 12, 2024”, 11 pgs. [cited by applicant]
“Chinese Application Serial No. 202110227749.X, Office Action mailed Jul. 10, 2024”, w English Translation, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-178075, Response filed Aug. 13, 2024 to Notification of Reasons for Rejection mailed May 14, 2024”, W English Claims, 9 pgs. [cited by applicant]
Sugimoto, Ayurni, “Nervous Control of Glucose Metabolism in the Liver”, W English translation Lifestyle Research vol. 3, No. 1, 138-141, (2001), 10 pgs. [cited by applicant]
“U.S. Appl. No. 17/719,032, Response filed Jul. 16, 2025 to Restriction Requirement mailed Jun. 10, 2025”, 8 pgs [cited by applicant]
“European Application Serial No. 24205384.1, Response filed Jul. 11, 2025 to Extended European Search Report mailed Dec. 12, 2024”, w claims, 13 pgs [cited by applicant]
“European Application Serial No. 15853911.4, Communication Pursuant to Article 94(3) EPC mailed Jul. 14, 2025”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/719,032, Non Final Office Action mailed Sep. 24, 2025”, 9 pgs. [cited by applicant]
“Chinese Application Serial No. 202110227749.X, Decision of Rejection mailed Feb. 20, 2025”, w English Translation, 7 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-478135, Response filed May 2, 2025 to Final Notification of Reasons for Rejection mailed Jan. 7, 2025”, w english claims, 23 pgs. [cited by applicant]
“Japanese Application Serial No. 2025-076723, Voluntary Amendment filed May 27, 2025”, w english claim, 8 pgs. [cited by applicant]
“U.S. Appl. No. 17/719,032, Restriction Requirement mailed Jun. 10, 2025”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 18/144,368, Corrected Notice of Allowability mailed Dec. 16, 2024”, 6 pgs. [cited by applicant]
“European Application Serial No. 24205384.1, Extended European Search Report mailed Dec. 12, 2024”, 13 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-178135, Final Notification of Reasons for Rejection mailed Jan. 7, 2025”, W English Translation, 8 pgs. [cited by applicant]
“Chinese Application Serial No. 202110227749.X, Response filed Dec. 30, 2024 to Office Action mailed Oct. 31, 2024”, w english claims, 14 pgs. [cited by applicant]
“European Application Serial No. 22826521.1, Response to Communication Pursuant to Rules 161 and 162 EPC Filed Dec. 20, 2024”, 14 pgs. [cited by applicant]